Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTaP/PRP-T Combined Vaccine · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Study Group 1 | EXPERIMENTAL | Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age. |
| Study Group 2 | EXPERIMENTAL | Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age. |
| Study Group 3 | ACTIVE_COMPARATOR | Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age. |
| Name | Type | Description |
|---|---|---|
| DTaP//PRP-T Combined Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
| DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (each vaccine) |
Inclusion Criteria : * Aged 2 months on the day of inclusion * Born at full term pregnancy (≥ 36 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or legal representative * Participant and parent/legal representative able to attend all scheduled visits and to compl...
DTaP/PRP-T Combined Vaccine is used for the prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type B infections. It is a combination vaccine being developed for use in infants, as studied in a Phase 3 clinical trial in China.
Sanofi (ticker: SNY) is developing DTaP/PRP-T Combined Vaccine. The company conducted a Phase 3 clinical trial of the vaccine in healthy infants in China.
DTaP/PRP-T Combined Vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
DTaP/PRP-T Combined Vaccine has one completed Phase 3 trial, NCT01062477, which enrolled 1,056 healthy infants in China. The trial compared the combined vaccine to local DTaP and Act-HIB monovalent vaccines.
Yes, DTaP/PRP-T Combined Vaccine is also known as ACTACEL. In the clinical trial NCT01062477, the vaccine is referred to as ACTACEL and was studied against local DTaP and Act-HIB vaccines.